Format

Send to

Choose Destination
See comment in PubMed Commons below
Ann Pharmacother. 2006 Feb;40(2):185-90. Epub 2006 Jan 24.

Outcomes of bupropion therapy for smoking cessation during routine clinical use.

Author information

1
Research and Performance Support, Regina Qu'Appelle Health Region, Regina, Saskatchewan, Canada. elan.paluck@rqhealth.ca

Abstract

BACKGROUND:

Knowledge pertaining to the effectiveness of smoking cessation treatments and patient characteristics that may affect success may enable smokers and clinicians to select individualized treatment for each patient and ultimately increase the success rate of smoking cessation in general.

OBJECTIVE:

To evaluate the effectiveness of bupropion as a smoking cessation agent when used in routine clinical practice.

METHODS:

This was a prospective, observational study with a one year follow-up period. Adult smokers presenting to community pharmacies in British Columbia, Canada, with an index prescription for bupropion for smoking cessation (N = 205) were eligible. The primary outcome was the biochemically validated 12 month point abstinence (PA) rate from smoking. Secondary outcomes included the frequency of adverse events, patterns of bupropion use in routine clinical practice, and possible predictors of bupropion effectiveness.

RESULTS:

The validated 12 month PA rate was 21.0%. Of subjects who reported taking at least one dose of bupropion, 70.4% (126/179) experienced at least one adverse event and 29.6% (53/179) reported stopping the drug due to adverse effects. Greater length of time on bupropion (OR 0.98) and a lower cigarette pack-year history (OR 1.05) were associated with an increase in the odds of smoking cessation.

CONCLUSIONS:

Subjects receiving bupropion in a real-life setting exhibited a similar abstinence rate at 12 months as has been observed in the active drug groups of placebo-controlled clinical trials. However, the patterns of use and discontinuation rate due to adverse events differed substantially from those observed in early efficacy studies.

PMID:
16434561
DOI:
10.1345/aph.1G324
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Atypon
    Loading ...
    Support Center